metformin + pioglitazone + acetyl-l-carnitine

The combination of metformin, pioglitazone, and acetyl-L-carnitine (ALC) is a therapeutic approach used primarily for treating type 2 diabetes and polycystic ovary syndrome (PCOS). This combination leverages the complementary mechanisms of each component to improve metabolic parameters. Metformin works by reducing glucose production in the liver, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Pioglitazone is a thiazolidinedione that acts as an insulin sensitizer by helping your body use insulin more effectively. It works by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). Acetyl-L-Carnitine (ALC) appears to enhance the effects of the other two medications by further improving insulin sensitivity and addressing metabolic alterations. Research indicates it may be particularly beneficial in treating PCOS-related symptoms. When used in combination, these medications have shown significant benefits: - Superior insulin resistance reduction compared to metformin plus pioglitazone alone - Improvement in polycystic ovaries and menstrual irregularities - Reduction in body circumference measurements - Decreased stress scores in patients with PCOS - Normalization of menstrual cycles (97.2% in the combination group vs. only 12.9% in the metformin plus pioglitazone group) - Improved endocrine parameters including decreased testosterone, FSH, and LH levels - Enhanced adiponectin levels, which helps regulate glucose levels and fatty acid breakdown The combination therapy requires careful monitoring for potential side effects, including lactic acidosis risk (metformin), fluid retention and edema (pioglitazone), and is contraindicated in patients with established NYHA Class III or IV heart failure.

Other names

Triple Drug Cocktail in PCOSmetformin + pioglitazone-Khyber Medical University Peshawar-polycystic ovary syndrome